Cleerly uses proprietary and FDA-cleared machine learning algorithms to non-invasively measure atherosclerosis (plaque), stenosis, and likelihood of ischemia using coronary computed tomography angiography (CCTA) studies.
Our machine-learning AI generates a 3D model of the patient’s coronary arteries, identifies their lumen and vessel walls, locates and measures stenoses, while quantifying and categorizing plaque.1 Cleerly ISCHEMIA’s algorithm uses measurements based on invasive FFR data to determine the likelihood of vessel-level ischemia.2
These sets of quantitative measurements are presented in a comprehensive report to support providers in efficient diagnosis and personalized patient treatment. Physicians can also review results in depth via our interactive web platform.
Cleerly’s analyses are grounded in science, based on over 10 million images from over 40,000 patients gathered over a 15-year-period in landmark, multi-center clinical trials.3 In a number of clinical studies, Cleerly has shown to be comparable to invasive gold standards, including IVUS4, NIRS5, FFR6, OCT7 and QCA.8
NEW updates available now!
Updated provider reports now include lesion-specific data
- Detailed information about each lesion in the provider report
- Reduces the need for follow-ups with consulting physicians
- Provides visual reference to help understand treatment options and behavior change
Full text reports integrated into PowerScribe
- CCTA reports transcribed and mapped to PowerScribe template
- Streamlined workflows
- Reduces manual data entry and errors
Measurable & actionable insights
Cleerly Reports include an interactive, web-based summary and details of our AI-based plaque, stenosis and ischemia analysis to help providers translate clinical data for personalized CAD diagnosis and treatment.
Provider reports include an interactive, web-based summary of findings and details on the total amount and type of plaque, severity of stenoses, and likelihood of ischemia within individual vessels.
